Premium
Evidence for Sialylated Type 1 Blood Group Chains on Human Erythrocyte Membranes Revealed by Agglutination of Neuraminidase‐Treated Erythrocytes with Waldenström's Macroglobulin IgM woo and Hybridoma Antibody FC 10.2
Author(s) -
Picard Jean K.,
Loveday Danuta,
Feizi Ten
Publication year - 1985
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1985.tb00141.x
Subject(s) - neuraminidase , hemagglutination , antibody , agglutination (biology) , antigen , monoclonal antibody , abo blood group system , chemistry , microbiology and biotechnology , red blood cell , virology , biology , biochemistry , immunology , virus
Haemagglutination studies have been performed with untreated and neuraminidase‐treated human erythrocytes of the three Lewis antigen types Le(a ‐ b ‐ ), Le (a+b ‐ ) and Le(a ‐ b+) using two monoclonal antibodies, IgM woo and FC 10.2, which were previously shown to recognize the type 1 based blood group chains: Galβl→3GlcNAcβl→3Galβl→4Glc/GlcNAc (for explanation of abbreviations see table IV legend). Both antibodies behaved as cold agglutinins with neuraminidase‐treated but not with untreated erythrocytes of the three Lewis antigen types. Neuraminidase‐treated erythrocytes of i antigen type were similarly agglutinated. This haemagglutination was specifically inhibited by the type 1 based milk oligosaccharide lacto‐N‐tetraose. Thus, there is strong evidence for the occurrence of sialylated type 1 chains on human erythrocyte membranes of I and i antigen types. In addition, evidence for the presence of type 1 chains which are both sialylated and fucosylated was obtained by (1) haemagglutination of Le(a+b ‐ ) erythrocytes with the monoclonal antibody 19.9; (2) increased haemagglutination of neuraminidase‐treated erythrocytes with anti‐H antibodies of Bombay serum; (3) increased haemagglutination of neuraminidase‐treated Le(a+b ‐ ) cells with anti‐Le a antibodies, and (4) the appearance of Le a antigen activity on neuraminidase‐treated erythrocytes of Le(a ‐ b+) type.